AC01
Heart Failure with Reduced Ejection Fraction (HFrEF)
Phase 2Active
Key Facts
Indication
Heart Failure with Reduced Ejection Fraction (HFrEF)
Phase
Phase 2
Status
Active
Company
About AnaCardio
AnaCardio is a Swedish biotech advancing a novel class of inotropic agents for heart failure, based on pioneering ghrelin pathway research from Karolinska Institutet. Its lead candidate, AC01, has demonstrated positive Phase 2a topline results in HFrEF patients, positioning it for rapid advancement into Phase 2b. The company is targeting a significant unmet need for a therapy that safely improves contractility without the dangerous side effects associated with current inotropes, across chronic, acute, and advanced heart failure settings.
View full company profileTherapeutic Areas
Other Heart Failure with Reduced Ejection Fraction (HFrEF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | FDA Approved / PMA |
| ALLAY-HFrEF | Alleviant Medical | Pivotal Trial |
| Neucardin® | Zensun Sci & Tech | Phase 2/3 |
| Cardiac Contractility Modulation (CCM) Implant | Berlin Heals | Pre-clinical / Early Clinical |
| SRD001 (inferred) | Sardocor | Phase 1 |
| Undisclosed HFrEF Program | NanoPhoria Bioscience | Preclinical |
| Firibastat | Quantum Genomics | Phase II |
| Omecamtiv Mecarbil | Cytokinetics | Phase 3 |